Grabar Law Office is investigating claims on behalf of shareholders of Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP). The investigation concerns whether certain officers and directors of Medpace breached their fiduciary duties owed to the Company.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials.

If you purchased Medpace Holdings, Inc. (NASDAQ: MEDP) shares prior to April 22, 2025, and continue to hold shares today, you are encouraged to contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You may be able to seek corporate governance reforms, the return of funds back to the Company, and a court-approved incentive award at no cost to you whatsoever. Alternatively, if you purchased or acquired Medpace securities between April 22, 2025 and February 9, 2026, you may be able to participate in the pending securities fraud class action.

Why? According to a recently filed federal securities fraud class action complaint, Medpace and certain of its officers allegedly misled investors concerning the Company’s projected book-to-bill ratio and backlog cancellation rates.Specifically, the complaint alleges that defendants repeatedly represented to investors throughout 2025 that Medpace could achieve a book-to-bill ratio of approximately 1.15 during the second half of 2025, while at the same time allegedly concealing material adverse information regarding elevated cancellation rates and the true state of the Company’s backlog.

The complaint further alleges that Medpace repeatedly described cancellations as “well behaved,” and represented that cancellations were not indicative of weakness in the Company’s business environment or funding environment.

On February 9, 2026, Medpace disclosed fourth quarter 2025 results revealing a net book-to-bill ratio of only 1.04, substantially below prior guidance.

The following day, Medpace management disclosed that “cancellations were elevated again in Q4,” and that backlog cancellations were “the highest they’ve been in over a year.”

On this news, the price of Medpace stock fell from $530.35 per share on February 9, 2026 to $446.05 per share on February 10, 2026 — a decline of more than 15.9%.

What You Can Do Now: If you purchased or otherwise acquired Medpace Holdings, Inc. (NASDAQ: MEDP) shares prior to April 22, 2025, and still hold shares today, you may have legal claims and may be able to seek corporate reforms, the return of funds back to the Company, and a court-approved incentive award at no cost to you whatsoever. If you purchased or acquired Medpace securities between April 22, 2025 and February 9, 2026, you may also be eligible to participate in the pending securities fraud class action.

For more information, please contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.